98%
921
2 minutes
20
Over the past two decades, the escalating prescription of opioid medications for pain management has culminated in a widespread opioid epidemic, significantly impacting public health, social dynamics, and economic stability. The urgent need for improved treatments for opioid addiction necessitates a deeper understanding of its biological underpinnings, with genetic variations playing a crucial role in individual susceptibility to opioid use disorder (OUD) and influencing clinical practices. In this study, we leverage the genetic diversity of four rat strains (ACI/N, BN/NHsd, WKY/N, and F344/N) to examine the contribution of genetic factors to oxycodone metabolism and addiction-like behaviors. We used the extended access to intravenous oxycodone self-administration procedure (12 h/day, 0.15 mg/kg/injection) to comprehensively characterize oxycodone-related behaviors and pharmacokinetics. We measured escalation of oxycodone self-administration, motivation for drug consumption, tolerance to the analgesic effects of oxycodone, withdrawal-induced hyperalgesia, and oxycodone-induced respiratory depression. Additionally, we examined oxycodone-seeking behavior after four weeks of withdrawal by reintroducing the animals to environmental and cue stimuli previously associated with oxycodone self-administration. The findings revealed notable strain differences in several behavioral measures, including oxycodone metabolism. Intriguingly, BN/NHsd and WKY/N strains exhibited similar drug intake and escalation patterns but displayed significant disparities in oxycodone and oxymorphone metabolism. Minimal sex differences were observed within strains, primarily relating to oxycodone metabolism. In conclusion, this study identifies strain differences in the behavioral responses and pharmacokinetics associated with oxycodone self-administration in rats, providing a robust foundation for identifying genetic and molecular variants associated with various facets of the opioid addiction process.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353778 | PMC |
http://dx.doi.org/10.1016/j.neuropharm.2023.109635 | DOI Listing |
Front Pharmacol
August 2025
Molecular Neuropsychiatry Research Branch, DHHS/NIH/NIDA Intramural Research Program, Baltimore, MD, United States.
Background: The number of individuals diagnosed with opioid use disorder (OUD) has risen steeply because of increased prescribing of opioid drugs including oxycodone for chronic pain relief. When rats given extended access to oxycodone only a subset of animals self-administers more drug over time. Identifying the molecular mechanism associated with this behavior can introduce novel ways to combat OUD.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Molecular Neuropsychiatry Research Branch, DHHS/NIH/NIDA Intramural Research Program, 251 Bayview Boulevard, Baltimore, MD 21224, USA.
The diagnosis of opioid use disorder (OUD) is prevalent due to increased prescribing of opioids. Long-term oxycodone self-administration can lead to addiction-like behavioral responses in rats. Herein, we sought to identify molecular pathways consequent to long-term exposure to oxycodone self-administration.
View Article and Find Full Text PDFbioRxiv
May 2025
Department of Psychiatry, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Alcohol use disorder (AUD) imposes a significant global health burden, yet effective treatments remain limited due to the scarcity of well-characterized biological sample repositories. To address this gap, we established the UCSD Alcohol BioBank, a comprehensive resource containing thousands of samples from over 700 genetically diverse heterogeneous stock (HS) rats. Modeled after successful cocaine and oxycodone biobanks, this repository utilizes the chronic intermittent ethanol vapor exposure (CIE) model, paired with oral self-administration, to characterize AUD-like behaviors, including ethanol consumption, preference, motivation, and withdrawal symptoms such as allodynia and anxiety-like behavior.
View Article and Find Full Text PDFBrain Behav
July 2025
Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.
Introduction: Despite the widespread impact of opioid use disorder, pharmacological options for treatment remain limited. Recent studies find that cocaine exposure decreases the expression of the glutamate transporter GLT-1 in the nucleus accumbens (NAc) and that treatment with the beta-lactam antibiotic ceftriaxone rescues this loss of expression and reduces cue-induced reinstatement to cocaine self-administration. The novel beta-lactam derivative MC-100093 (093) lacks antimicrobial properties but crosses the blood-brain barrier more rapidly and retains the beneficial effects of ceftriaxone following cocaine.
View Article and Find Full Text PDFbioRxiv
May 2025
Department of Pharmacology, Addiction Science, and Toxicology, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
Individual vulnerability to opioid intake escalation is a critical but poorly understood aspect of addiction. Using genetically diverse inbred rat strains, we investigated operant oral oxycodone self-administration, identifying 'Augmenter' phenotypes that dramatically increased consumption during extended (16h vs. 4h) access-a vulnerability not predicted by standard motivation tests.
View Article and Find Full Text PDF